Moleculin Biotech Says EMA Grants Orphan Drug Designation To

Pharmaceutical company Moleculin Biotech, Inc. (MBRX) announced Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of Acute Myeloid Leukemia (AML).

Related Keywords

, Moleculin Biotech Inc , Drug Administration , European Medicines Agency , Moleculin Biotech , Orphan Drug Designation , Acute Myeloid Leukemia , Fast Track Status ,